On Friday, Tango Therapeutics Inc (NASDAQ: TNGX) was 6.29% up from the session before settling in for the closing price of $11.06. A 52-week range for TNGX has been $1.03 – $12.11.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 7.47%. When this article was written, the company’s average yearly earnings per share was at 26.81%. With a float of $88.65 million, this company’s outstanding shares have now reached $111.57 million.
Tango Therapeutics Inc (TNGX) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Tango Therapeutics Inc stocks. The insider ownership of Tango Therapeutics Inc is 34.17%, while institutional ownership is 73.15%. The most recent insider transaction that took place on Oct 23 ’25, was worth 4,846,575. In this transaction 10% Owner of this company sold 477,401 shares at a rate of $10.15, taking the stock ownership to the 13,386,574 shares. Before that another transaction happened on Oct 23 ’25, when Company’s 10% Owner proposed sale 477,401 for $7.53, making the entire transaction worth $3,594,830.
Tango Therapeutics Inc (TNGX) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.34 earnings per share (EPS) during the time that was better than consensus figure (set at -0.34) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 26.81% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -4.76% during the next five years compared to 7.47% growth over the previous five years of trading.
Tango Therapeutics Inc (NASDAQ: TNGX) Trading Performance Indicators
You can see what Tango Therapeutics Inc (TNGX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.88. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 22.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.92, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.25 in one year’s time.
